Eli Lilly (NYSE: LLY) has seen its stock decline over 18% this year, underperforming the S&P 500 amid concerns over the sustainability of demand for its popular GLP-1 drugs, Zepbound and Mounjaro. Despite this downturn, CEO Dave Ricks suggests that potential Medicare coverage for obesity drugs could serve as a significant catalyst for growth, potentially reversing the current trend.
The healthcare sector is closely monitoring Eli Lilly’s developments, particularly as the company has been generating strong growth from its anti-obesity drug portfolio. If Medicare were to cover these treatments, it could not only boost sales but also enhance patient health outcomes, reducing future medical costs and benefiting the overall healthcare industry.
For market professionals, this presents an intriguing opportunity: while Eli Lilly’s stock appears expensive at 38 times trailing earnings, the anticipated Medicare coverage could unlock substantial upside, making it a compelling long-term investment despite current market skepticism.
Source: fool.com